- Therapeutic potential of cannabinoids in schizophreniaJana Kucerova
CEITEC Central European Institute of Technology Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
Recent Pat CNS Drug Discov 9:13-25. 2014..Furthermore, this review will be highlighting the therapeutic potential of cannabinoid-related compounds and presenting some promising patents targeting potential treatment options for schizophrenia. ..
- The Dopamine and Cannabinoid Interaction in the Modulation of Emotions and Cognition: Assessing the Role of Cannabinoid CB1 Receptor in Neurons Expressing Dopamine D1 ReceptorsAna Luisa Terzian
Research Group Neuronal Plasticity, Max Planck Institute of Psychiatry Munich, Germany
Front Behav Neurosci 5:49. 2011..These results provided first direct evidence for a cross-talk between dopaminergic D1Rs and endocannabinoid system in terms of controlling negative affect...
- Endocannabinoid system and mood disorders: priming a target for new therapiesVincenzo Micale
CEITEC Central European Institute of Technology Masaryk University, Brno, Czech Republic
Pharmacol Ther 138:18-37. 2013..The state of the art of the possible therapeutic use of endocannabinoid deactivation inhibitors and phytocannabinoids in mood disorders is discussed in this review article...
- Leading compounds for the validation of animal models of psychopathologyVincenzo Micale
CEITEC Central European Institute of Technology, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic
Cell Tissue Res 354:309-30. 2013..We conclude that the generation of convincing and useful animal models of mental illnesses could be a bridge to success in drug discovery...